Paper Details

  1. Home
  2. Paper Details

Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA.

Author: ChoYong Suk, ChoiJong Won, JeonHan Ho, KimDong Hyun, LeeChun Kyon, ParkByung Kyu, SeoJeong Hun, ShinSang Yun, WonSun Young

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study examined the long-term effectiveness of switching from entecavir (ETV) to telbivudine (LdT) for treating chronic hepatitis B. The study found that switching to LdT resulted in virological rebound in 16.7% of patients. The study concluded that switching to LdT is not recommended after initial treatment with ETV.
Paper Details　
Original Abstract of the Article :
PURPOSE: This study examined 2-year outcome of consecutive therapy using entecavir (ETV) followed by telbivudine (LdT) in subjects with undetectable hepatitis B virus (HBV) DNA level and normal alanine aminotransferase level after the initial 6 months of ETV treatment. MATERIALS AND METHODS: Sixty ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368140/

データ提供：米国国立医学図書館（NLM）

Switching Therapies for Chronic Hepatitis B

Hepatitis B is a serious liver infection, and the search for effective treatment strategies is an ongoing endeavor. This study explores the effectiveness of switching from entecavir to telbivudine therapy in patients with undetectable hepatitis B virus (HBV) DNA levels. It's like navigating a complex network of paths in the desert of viral infections, seeking the most effective route to control this disease.

The Effectiveness of Switching Therapies

This study found that switching from entecavir to telbivudine therapy resulted in virological rebound in a significant number of patients. While telbivudine is a more potent antiviral agent than lamivudine, the study suggests that switching from entecavir to telbivudine may not be the optimal strategy for managing chronic hepatitis B. It's like finding a seemingly promising oasis in the desert, only to discover that it's not as sustainable as it initially appeared.

The Importance of Long-Term Monitoring

This study highlights the importance of long-term monitoring and careful consideration of treatment strategies for chronic hepatitis B. It's crucial to weigh the potential benefits and risks of switching therapies, ensuring that patients receive the most effective treatment for their individual needs. It's like navigating the desert with a keen eye, carefully assessing the landscape and choosing the best path forward.

Dr. Camel's Conclusion

This study is like a camel caravan exploring the complexities of hepatitis B treatment. While switching from entecavir to telbivudine may not be the optimal strategy for all patients, the research provides valuable insights into the nuances of viral infection management. It's a reminder that the desert of medical science is vast and ever-changing, and we must remain vigilant in our pursuit of effective treatments for challenging diseases.

Date :
  1. Date Completed 2017-05-02
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

28332360

DOI: Digital Object Identifier

PMC5368140

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.